What would it take to get peptides on the shelf?

Key Points:

• An FDA advisory panel voted to support the production of six out of seven experimental peptide therapies, including popular injectables like BPC-157, TB-500, and MOTS-c, but these drugs remain illegal for U.S. pharmacies to compound until further FDA review.
• The FDA staff and leadership must decide whether to allow compounding pharmacies to produce these peptides, with potential expedited approval routes being considered due to high demand and pressure from Health Secretary Robert F. Kennedy Jr.
• Peptides have become controversial because they are widely used for wellness and longevity despite lacking large-scale human trials or FDA approval, leading to a risky gray market where unregulated products are sold for research purposes.
• If approved, these peptides will require prescriptions and will likely be available only through compounding pharmacies rather than traditional drugstores, with a variable timeline for availability depending on supply chain factors.
• Medical experts caution that commercial enthusiasm for peptides is ahead of clinical evidence, and while some doctors and clinics promote their use, there are no established, evidence-based guidelines or FDA approval for these therapies yet.